About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...

Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

Most recently, Denali Therapeutics initiated dosing in a global BEACON Phase 2a trial of BIIB122 (DNL151) for LRRK2-associated Parkinson’s disease. Denali’s market cap stands at $2.93 billion ...

Russellville-based Denali Water Solutions LLC, the primary defendant in a lawsuit in which attorneys ask for class-action status, requests the suit against it and Alma-based SSS of Crawford County ...

Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33. Get Denali Therapeutics alerts: Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its ...

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for neurodegenerative diseases. The analyst highlights that Denali is developing a ...

Denali was visible from Point Woronzof in Anchorage on Wednesday, Oct. 9, 2024, as a person rides a bicycle on the Tony Knowles Coastal Trail. (Bill Roth / ADN) I guess it makes sense that a ...

Denali Therapeutics (NASDAQ:DNLI) Inc. has reached a new 52-week high, with its stock price climbing to $32.17. This milestone reflects a significant surge in investor ...